{"gene":"ICAM3","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1992,"finding":"ICAM-3 (ICAM-R/CD50) is a member of the immunoglobulin superfamily with five extracellular Ig-like domains that binds LFA-1 (CD11a/CD18), functioning as a third ligand for LFA-1; it is constitutively expressed on all resting leukocytes but not on resting or cytokine-activated endothelial cells.","method":"Expression cloning of cDNA, cell adhesion assays, antibody blocking experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — two independent molecular cloning papers (PMID:1448173 and PMID:1448174) both established LFA-1 binding by direct adhesion assay and antibody blockade, replicated across labs","pmids":["1448173","1448174"],"is_preprint":false},{"year":1992,"finding":"ICAM-3 (CDw50) becomes phosphorylated on serine residues upon stimulation with protein kinase C activators (phorbol esters, mezerein) and by lymphocyte activation agents (ConA, PHA, anti-CD3 cross-linking); this phosphorylation is rapid, dose-dependent, and inhibited by PKC inhibitors staurosporine and H-7, but does not alter surface expression levels.","method":"Radiolabeling with 32P-orthophosphate, phosphoamino acid analysis, PKC inhibitor assays, flow cytometry","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical phosphorylation assays with pharmacological inhibitors in a single lab, multiple cell types tested","pmids":["1730238"],"is_preprint":false},{"year":1993,"finding":"ICAM-3 regulates the LFA-1/ICAM-1 adhesion pathway: engagement of ICAM-3 by activating anti-ICAM-3 mAb (HP2/19, epitope A) triggers LFA-1/ICAM-1-dependent T lymphoblast homotypic aggregation, increases T cell attachment to ICAM-1, and co-stimulates T lymphocyte proliferation with anti-CD3. ICAM-3 localizes to cellular uropods during aggregation, distinct from LFA-1 and ICAM-1 at intercellular boundaries.","method":"T cell adhesion assays on purified ICAM-3 surfaces, mAb blocking with anti-LFA-1 and anti-ICAM-1, immunofluorescence microscopy, proliferation assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal assays (adhesion, aggregation, imaging, proliferation) in a single study, replicated functionally by other labs","pmids":["7901223"],"is_preprint":false},{"year":1993,"finding":"CDw50 and ICAM-3 are the same glycoprotein (120 kDa surface molecule); identity established by immunochemical, functional, and protein sequencing studies.","method":"Protein sequencing, immunochemical cross-reactivity, functional adhesion assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct protein sequencing combined with functional and immunochemical validation","pmids":["8325327"],"is_preprint":false},{"year":1994,"finding":"The LFA-1 binding site on ICAM-3 resides in Ig-like domain 1, which is necessary and sufficient for LFA-1 binding; domain deletion and chimera analysis identified five residues (Asn23, Ser25, Glu37, Phe54, Gln75) that contribute to the binding site, predicted to cluster on the BED face and C/E strands of domain 1 by molecular modeling.","method":"Domain deletion mutants, ICAM-3/CD21 chimeras, site-directed mutagenesis (45 point mutants), LFA-1 adhesion assays, epitope mapping with 17 mAbs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis with 45 point mutants combined with domain-deletion chimeras and multiple mAb epitope mapping in a single rigorous study","pmids":["8798624"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 engagement activates ICAM-3-independent (LFA-1/ICAM-1-independent) cell aggregation in JM T cells and HAFSA B cells; this aggregation involves tyrosine phosphorylation and is regulated by the CD45 tyrosine phosphatase — anti-CD45 mAbs and tyrosine kinase inhibitors abolish ICAM-3-induced aggregation. Tyrosine-phosphorylated proteins (125, 70, 38 kDa) accumulate at intercellular boundaries upon ICAM-3 or LFA-1 engagement.","method":"mAb blocking assays, tyrosine kinase inhibitors (herbimycin A), CD45 inhibitors, immunofluorescence, Western blot of phosphotyrosine","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pharmacological inhibitors, blocking antibodies, immunofluorescence, Western blot) in one study, replicated in multiple cell lines","pmids":["7520448"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 engagement by activating mAb (HP2/19) enhances T lymphoblast adhesion to ICAM-1, VCAM-1, fibronectin fragments (FN40, FN80) via increased LFA-1 and VLA-4/VLA-5 avidity, and induces a dramatic uropod-like morphological change with exclusive redistribution of ICAM-3 to the distal uropod tip, while LFA-1 and VLA-β1 remain distributed over the contact area.","method":"Cell adhesion assays, mAb blocking, immunofluorescence microscopy, phorbol ester controls","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional adhesion assays with integrin-specific blocking mAbs and direct imaging, multiple substrates, single lab with extensive controls","pmids":["7525599"],"is_preprint":false},{"year":1994,"finding":"Purified ICAM-3 supports LFA-1-dependent T cell adhesion in a temperature- and cation-dependent manner. Combined mAbs to ICAM-1, ICAM-2, and ICAM-3 achieve near-complete inhibition of LFA-1-dependent lymphocyte proliferative responses (PHA, allogeneic cells, specific antigen), suggesting these three molecules account for most or all functional LFA-1 ligands. ICAM-3 also provides a co-stimulatory signal for resting T lymphocyte proliferation.","method":"Adhesion assays on purified ICAM-3, mAb blocking of PBL proliferation (PHA, MLR, antigen), T cell co-stimulation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstituted adhesion with purified protein plus systematic mAb blocking across multiple functional assays, replicated across conditions","pmids":["7905020"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 is a ligand for αdβ2 (CD11d/CD18), a novel fourth β2 integrin that shows preferential binding to ICAM-3 over ICAM-1.","method":"cDNA cloning of αd chain, transfection, cell adhesion assays comparing ICAM-3 vs ICAM-1 binding","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — identification of new integrin with molecular cloning plus direct binding comparison, replicated later by multiple labs","pmids":["8777714"],"is_preprint":false},{"year":1994,"finding":"Cross-linking CD50 (ICAM-3) on Jurkat T cells induces calcium mobilization (primarily via extracellular Ca2+ influx) and tyrosine phosphorylation; p56lck and p59fyn protein tyrosine kinases are found in CD50 immunoprecipitates, implicating these Src-family kinases in CD50 signal transduction.","method":"Anti-CD50 cross-linking, intracellular Ca2+ measurement, phosphotyrosine immunoprecipitation, in vitro kinase assays, specific antisera co-immunoprecipitation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assays plus co-IP demonstrating physical association of p56lck and p59fyn, multiple methods in a single study","pmids":["7515097"],"is_preprint":false},{"year":1994,"finding":"Signaling through CD50 (ICAM-3) increases T lymphocyte adhesion to TNF-stimulated endothelial cells and extracellular matrix proteins by increasing β1 and β2 integrin avidity, without altering surface integrin expression levels.","method":"Anti-CD50 mAb stimulation, adhesion to HUVEC and ECM proteins, mAb blocking of β1 and β2 integrins, ICAM-1 transfectant binding, flow cytometry for integrin surface expression","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple adhesion substrates and integrin-specific blocking, single lab","pmids":["7515813"],"is_preprint":false},{"year":1994,"finding":"The I domain of LFA-1's α subunit contains the binding site for both ICAM-1 and ICAM-3; two I domain mAbs (YTH81.5 and 122.2A5) selectively block ICAM-3 but not ICAM-1 binding, and one I domain mAb (MEM-83) activates binding to ICAM-1 but not ICAM-3, demonstrating that LFA-1 can selectively engage these two highly homologous ligands through the I domain.","method":"T cell binding assays to ICAM-1 or ICAM-3-coated plastic, LFA-1 transfected COS cell adhesion assays, mAb epitope mapping to I domain","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematically tested panel of 29 mAbs with two independent cell-based assay formats, I domain epitopes confirmed","pmids":["7518468"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 is a co-stimulatory molecule for both resting and activated T lymphocytes: soluble ICAM-3 or anti-ICAM-3 mAbs co-immobilized with sub-optimal anti-CD3 stimulate CD25 and CD69 expression; this activation is blocked by anti-CD18 mAb, implicating LFA-1 (via its β2 chain) as the mediating integrin. Anti-ICAM-3 (but not anti-ICAM-1) co-stimulates resting cord blood T cells.","method":"Co-stimulation assays with immobilized ICAM-3 and anti-CD3, flow cytometry for activation markers (CD25, CD69), mAb blocking with anti-CD18","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct blocking with anti-CD18, multiple cell types (resting and activated), single lab","pmids":["8223855"],"is_preprint":false},{"year":1994,"finding":"The LFA-1 binding site in ICAM-3 is in the amino-terminal (domain 1) IgSF domain; electron microscopy shows ICAM-3 is a 15 nm straight rod with head-to-tail domain arrangement; residues E37/T38 form a conserved integrin binding site motif also found in ICAM-1 and VCAM-1, while Q75 may confer LFA-1 binding specificity.","method":"Electron microscopy, domain deletion mutants, site-directed mutagenesis, mAb blocking adhesion assays","journal":"Cell adhesion and communication","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EM structural characterization combined with mutagenesis and functional adhesion assays in a single study","pmids":["7531103"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 surface expression on activated neutrophils is rapidly downregulated by a proteolytic shedding mechanism (not internalization): protease inhibitors block PMA-induced downregulation, and ICAM-3 is detected in cell-free supernatants and in plasma (0-296 ng/ml). The remaining ICAM-3 on the neutrophil surface still supports anti-ICAM-3-triggered homotypic aggregation.","method":"Immunofluorescence flow cytometry, 125I-labeled mAb internalization assay, immunoprecipitation of supernatants, radioimmunoassay of plasma, protease inhibitor studies","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (internalization assay ruling out endocytosis, protease inhibition, direct detection of shed protein, functional assay) in a single study","pmids":["7525295"],"is_preprint":false},{"year":1994,"finding":"ICAM-3 is not a ligand for Mac-1 (CD11b/CD18) or p150,95 (CD11c/CD18): purified ICAM-3 from lymphoid cells and neutrophils does not support adhesion of Mac-1- or p150,95-expressing CHO transfectants, and purified Mac-1 does not support adhesion of ICAM-3-expressing L cell transfectants, despite ICAM-3 being well expressed on neutrophils where Mac-1 is abundant.","method":"Cell adhesion assays with CHO and L cell transfectants expressing specific integrins, homotypic aggregation assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — rigorous negative result using purified proteins and transfectants expressing defined integrins, bidirectional assay","pmids":["7737271"],"is_preprint":false},{"year":1995,"finding":"CD50 (ICAM-3) is phosphorylated on tyrosine in human neutrophils (predominantly phosphotyrosine by phosphoamino acid analysis); phosphorylation increases transiently (peak ~1 min) after stimulation with FMLP, PAF, PMA, or calcium ionophore. Tyrosine kinase activity is detected in CD50 immunoprecipitates from solubilized neutrophils.","method":"Radiolabeling ecto-kinase assay, phosphoamino acid analysis, immunoprecipitation in vitro kinase assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay in immunoprecipitate with phosphoamino acid analysis, single lab","pmids":["7876557"],"is_preprint":false},{"year":1995,"finding":"A circulating/soluble form of ICAM-3 (sCD50) is produced by lymphocytes upon activation (particularly CD3 triggering), is proteolytically cleaved from the cell membrane (apparent MW ~95 kDa vs membrane ~120 kDa by immunoblot), and is detectable in normal human serum; sCD50 levels are elevated in SLE patients and correlate positively with sCD27 levels.","method":"Sandwich ELISA, immunoblot of culture supernatants, Northern blot kinetics, flow cytometry for surface expression","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (ELISA, immunoblot, Northern blot) with size comparison suggesting cleavage, single lab","pmids":["7876564"],"is_preprint":false},{"year":1996,"finding":"Stimulation through CD50 (ICAM-3) on human thymocytes by mAb cross-linking induces calcium mobilization and CD69 (but not CD25) expression; co-cross-linking with CD45 inhibits calcium mobilization, implicating tyrosine phosphorylation in CD50 signaling. CD50 cross-linking also increases activation-induced cell death of thymocytes.","method":"mAb cross-linking, intracellular Ca2+ measurement, co-cross-linking with anti-CD45, flow cytometry for activation markers, apoptosis assays","journal":"Tissue antigens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional signal transduction assays with CD45 co-cross-linking demonstrating regulatory interaction, single lab","pmids":["9008304"],"is_preprint":false},{"year":1997,"finding":"The LFA-1 I domain alone (expressed as GPI-anchored) is sufficient to mediate transient, Mg2+-dependent rolling adhesion on ICAM-1 and ICAM-3 in hydrodynamic flow. MEM-83 (activating I domain mAb) decreased rolling velocity on ICAM-1 but blocked rolling on ICAM-3, demonstrating that ICAM-3 interaction with the I domain is blocked by this conformational change.","method":"Stable GPI-anchored I domain expression, flow cell rolling assays on lipid bilayers with purified ICAM-1 or ICAM-3, activating mAb (MEM-83) treatment, divalent cation substitution","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted rolling adhesion assay with defined I domain construct and purified ligands, divalent cation dependency established","pmids":["9271587"],"is_preprint":false},{"year":1998,"finding":"The LFA-1 binding site on ICAM-3 domain 1 is more extensive than that of ICAM-1, involving residues on both the ABED face and GFC face; point mutagenesis of 18 residues identified 7 that reduce or abolish LFA-1 adhesion, including 3 on the A strand of the ABED face — a surface not used by ICAM-1 for LFA-1 binding.","method":"18-point mutagenesis of domain 1, LFA-1 adhesion assays, functional blocking mAb binding studies","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic site-directed mutagenesis with functional adhesion assays in a single focused study","pmids":["9686599"],"is_preprint":false},{"year":1998,"finding":"ICAM-3 engagement on monocytes and neutrophils by domain 1-directed triggering mAbs induces outside-in signaling: monocytes secrete chemokines MIP-1α, IL-8, and MCP-1; neutrophils secrete IL-8; monocytes show dramatic spreading via Fab/F(ab')2 fragments (excluding Fc-mediated effects). Co-engagement of ICAM-3 and Fc receptors (FcγRI or FcγRII) is required for maximal chemokine secretion by monocytes.","method":"Immobilized mAb engagement, ELISA for chemokines, Fab/F(ab')2 fragment controls, microscopy of cell spreading","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Fab fragment controls establish direct outside-in signaling, multiple readouts (chemokines, morphology), two cell types","pmids":["9605163"],"is_preprint":false},{"year":1998,"finding":"ICAM-3 engagement on PMN (by CAL3.10 mAb binding in the αLβ2 integrin-binding region) activates PMN homotypic aggregation and adhesion via outside-in signaling: β2 integrin-dependent mechanism, activates tyrosine and PKC kinases, and reorganizes the cytoskeleton without causing degranulation or increasing surface β2 integrin expression. A different anti-ICAM-3 mAb (HP2/19) does not activate PMN, demonstrating epitope-specificity.","method":"PMN aggregation assays, F(ab')2 fragment controls, anti-β2 integrin blocking, kinase activity assays, cytoskeleton reorganization assays, degranulation assays (elastase release), flow cytometry for β2 integrin expression","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — F(ab')2 fragments confirm direct outside-in signaling, multiple orthogonal readouts with appropriate controls for Fc vs direct signaling","pmids":["9834117"],"is_preprint":false},{"year":1999,"finding":"ICAM-3 on the surface of apoptotic leukocytes acquires altered receptor-binding activity: during apoptosis, the first Ig-like domain of ICAM-3 participates in macrophage recognition and phagocytosis of apoptotic cells. ICAM-3 on apoptotic cells switches binding preference from LFA-1 to an alternative macrophage receptor; mAb blockade of macrophage CD14 (but not αvβ3 or αdβ2) inhibited ICAM-3-dependent recognition of apoptotic cells.","method":"mAb blocking of macrophage-apoptotic cell interactions, ICAM-3 transfection into non-leukocytes, multiple apoptosis stimuli, domain 1-specific mAb characterization","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — transfection into non-leukocytes proves sufficiency, systematic mAb blocking of multiple candidate receptors, multiple apoptosis stimuli confirm generality","pmids":["10352301"],"is_preprint":false},{"year":2000,"finding":"DC-SIGN, a novel dendritic cell-specific C-type lectin, binds ICAM-3 expressed on resting T cells with high affinity and mediates transient DC-T cell adhesion required for initiation of primary immune responses; antibodies against DC-SIGN inhibit DC-induced proliferation of resting T cells.","method":"Identification of DC-SIGN by expression, binding assays, anti-DC-SIGN mAb inhibition of DC-T cell adhesion and T cell proliferation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor identification with functional validation using blocking antibodies and T cell proliferation assays, published in Cell, widely replicated","pmids":["10721994"],"is_preprint":false},{"year":2000,"finding":"LFA-1 binding to ICAM-3 (vs ICAM-1 or ICAM-2) produces distinct cytokine profiles in T cells: ICAM-2 and ICAM-3 co-stimulation induces stronger TNF-α secretion, whereas ICAM-1 co-stimulation induces higher IL-10 production, demonstrating that the specific ICAM ligand engaged by LFA-1 differentially shapes the Th1/Th2 cytokine output.","method":"T cell co-stimulation assays on immobilized ICAM-1, -2, or -3, cytokine ELISA (GM-CSF, IFN-γ, IL-2, IL-4, IL-5, IL-10, TNF-α), proliferation assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic comparison across all three ICAM ligands with multiple cytokine measurements, single lab","pmids":["10427988"],"is_preprint":false},{"year":2000,"finding":"LFA-1 binds ICAM-3 as its primary ligand supporting neutrophil homotypic adhesion at high shear rates (≥800 s-1), while Mac-1 predominates at low shear rates (~100 s-1); ICAM-3 supports LFA-1-mediated homotypic neutrophil aggregation with efficiency varying with shear rate and time post-stimulation.","method":"Cone-plate viscometer shear assay, flow cytometry aggregate quantification, mAb blocking of LFA-1, Mac-1, and ICAM-3, collision efficiency modeling","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative flow-based assay with mAb blocking and mathematical modeling, single lab","pmids":["10725740"],"is_preprint":false},{"year":2001,"finding":"ICAM-3 N-linked oligosaccharides are predominantly tri- and tetra-antennary complex-type (~6 mol/mol protein) with poly-N-acetyllactosamine chains; a small amount of high-mannose oligosaccharide (6 α-mannose residues) is present, which can serve as a ligand for DC-SIGN.","method":"Hydrazinolysis, paper electrophoresis, lectin column chromatography, sequential glycosidase digestion, methylation analysis, structural characterization","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic structural glycan analysis using multiple orthogonal methods (lectin chromatography, exo/endo-glycosidase, methylation analysis) in a single study","pmids":["11179968"],"is_preprint":false},{"year":2002,"finding":"ICAM-3 is specifically clustered at the region of the T lymphocyte surface that initiates contact with APCs before antigen recognition (as shown by time-lapse live imaging), and plays a role in T cell-APC conjugate formation, early intracellular signaling, and cytoskeletal rearrangement in the initial APC-scanning phase.","method":"Time-lapse live-cell imaging, antibody blocking of T cell-APC conjugate formation, early signaling assays, cytoskeletal rearrangement assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — live imaging directly demonstrates polarized ICAM-3 clustering at contact initiation site, functional blocking confirms role, multiple orthogonal readouts","pmids":["11812993"],"is_preprint":false},{"year":2004,"finding":"DC-SIGN binds to gp120 in a distinct but overlapping manner compared to ICAM-2 and ICAM-3: recombinant soluble DC-SIGN binds gp120 >100-fold and >50-fold better than ICAM-2-Fc and ICAM-3-Fc, respectively; Asp-367 mutation enhances gp120 binding but diminishes ICAM-2 and ICAM-3 binding, while Gly-346 mutation abrogates gp120 binding but enhances ICAM-2/ICAM-3 binding.","method":"Recombinant protein binding assays (ICAM-2-Fc, ICAM-3-Fc, gp120-Fc), alanine-scanning mutagenesis of DC-SIGN, monosaccharide/disaccharide competition, glycan chip analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic alanine-scanning mutagenesis combined with quantitative binding assays and glycan chip analysis identifying residues differentially required for ICAM vs viral ligands","pmids":["14970226"],"is_preprint":false},{"year":2006,"finding":"DC-SIGN binds native ICAM-3 isolated from peripheral leukocytes via Lewis x (Lex) carbohydrate residues; ICAM-3 from granulocytes (not lymphocytes) bears Lex residues mediating DC-SIGN binding; FUT IX is the primary fucosyltransferase mediating Lex synthesis on ICAM-3 in myeloid cells, with minor contribution from FUT IV.","method":"DC-SIGN binding assays with native ICAM-3, Lewis x mAb staining, MALDI-TOF mass spectrometry for Lex confirmation, cotransfection of FUT isoforms (FUT III, IV, VII, IX) with ICAM-3, flow cytometry","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — MS-confirmed glycan identification combined with FUT cotransfection experiments identifying specific biosynthetic enzyme, cell-type comparison","pmids":["17145745"],"is_preprint":false},{"year":2011,"finding":"Apoptotic cell-derived microparticles bearing ICAM-3 potently attract macrophages (chemoattraction) to sites of leukocyte cell death; ICAM-3 on apoptotic cells mediates domain 1-2-dependent tethering to phagocytes. Apoptosis causes reduction in cell-surface ICAM-3 via release within microparticles. Blocking mAb (MA4) that inhibits domain 1-2 of ICAM-3 blocks apoptotic cell clearance.","method":"Novel anti-ICAM-3 mAb blocking studies, ICAM-3-deficient apoptotic leukocytes, macrophage chemotaxis assays, microparticle isolation and characterization, phagocytosis assays","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — uses ICAM-3-deficient cells as negative control alongside blocking mAbs, identifies microparticle mechanism, multiple functional assays (chemotaxis and tethering separately assessed)","pmids":["22117198"],"is_preprint":false},{"year":2012,"finding":"ICAM-3 gene promoter activity is leukocyte-restricted and is negatively regulated by RUNX transcription factors: RUNX cognate sequences are required for promoter activity and RUNX3/Ets/C-EBP cooperative regulation; siRNA-mediated reduction of RUNX3 increases ICAM-3 mRNA levels. ICAM-3 protein levels decrease during monocyte-to-macrophage differentiation and monocyte transendothelial migration, correlating with RUNX3 increase.","method":"ICAM-3 promoter-reporter assays, chromatin immunoprecipitation (in vivo occupancy), RUNX-binding site mutagenesis, siRNA knockdown of RUNX3, protein analysis during differentiation/migration","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP confirms in vivo occupancy, promoter mutagenesis demonstrates requirement of RUNX sites, siRNA validates RUNX3 as negative regulator, multiple orthogonal methods","pmids":["22479382"],"is_preprint":false},{"year":2013,"finding":"ICAM-3 expressed on macrophages functions as a recognition receptor for apoptotic neutrophils: siRNA silencing and antibody blockade of ICAM-3 on macrophages (but not neutrophils) reduces phagocytosis; blocking ICAM-3 on apoptotic neutrophil surface also reduces uptake. ICAM-3 and LFA-1 (αL/β2) co-localize at phagocytic portals on macrophages; simultaneous knockdown causes marked phagocytosis deficiency.","method":"Gene silencing (siRNA), blocking antibodies, confocal microscopy of phagocytic portals, apoptotic neutrophil phagocytosis assay","journal":"Apoptosis","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA knockdown plus antibody blockade on both cell types combined with confocal imaging of phagocytic portals, replicated in multiple assays","pmids":["23775590"],"is_preprint":false},{"year":2010,"finding":"ICAM-3 overexpression in NSCLC cells increases cell migration and invasion by upregulating MMP-2 and MMP-9 expression and activity through a signaling pathway: ICAM-3 → Akt phosphorylation → CREB activation → MMP upregulation. Blocking the Akt pathway attenuates CREB activation and reduces MMP activity and migration/invasion, regardless of p53 or PTEN status.","method":"Stable ICAM-3-overexpressing transfectants, migration/invasion assays, MMP-2/9 activity assays, Akt phosphorylation Western blot, CREB activation assays, Akt pathway inhibitors, CREB siRNA","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable OE cell lines with pathway inhibitors and siRNA knockdown, validated in two NSCLC cell lines, single lab","pmids":["19956847"],"is_preprint":false},{"year":2018,"finding":"ICAM-3 promotes cancer cell stemness by recruiting and binding Src kinase via a YLPL motif in its intracellular domain, thereby activating PI3K-AKT signaling that enhances SOX2 and OCT4 activity; activated p-AKT also facilitates p50 nuclear translocation enhancing ICAM-3 promoter activity creating a positive feedback loop. ICAM-3 knockdown reduces side population, sphere formation, chemo-resistance, and tumor growth in vivo.","method":"siRNA screen, shRNA knockdown, Src co-immunoprecipitation with intracellular domain, Src/PI3K inhibitors, in vivo tumor xenograft, ALDH assay, sphere formation, p50 nuclear translocation assay, ICAM-3 promoter ChIP","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP identifies Src-ICAM3 interaction via intracellular domain, pathway inhibitors and in vivo validation, but single lab study","pmids":["29477378"],"is_preprint":false},{"year":2018,"finding":"ICAM-3 promotes tumor metastasis through a LFA-1-ICAM-3-ERM-lamellipodia mechanism: ICAM-3 binds LFA-1 via its extracellular domain and ERM proteins via its intracellular domain, creating mechanical tension that facilitates cell separation (metastasis). ICAM-3 extracellular or intracellular domain mutants abolish ICAM-3-mediated metastasis in vitro and in vivo; blocking LFA-1/ICAM-3 interaction with LFA-1 antibody or Lifitegrast reduces metastasis.","method":"Co-IP of LFA-1 and ERM with ICAM-3, extracellular/intracellular domain mutants, in vitro and in vivo metastasis assays, LFA-1 blocking antibody and Lifitegrast treatment","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus domain mutants with in vivo validation, single lab","pmids":["29729315"],"is_preprint":false},{"year":2011,"finding":"Kidins220/ARMS (a neuronal scaffold protein also expressed in T cells) co-localizes with and co-immunoprecipitates with ICAM-3 at the uropod of polarized T cells; this association requires cell polarity and is regulated by PKC. Kidins220/ARMS knockdown promotes basal and SDF-1α-induced T cell directed migration.","method":"Co-immunoprecipitation, confocal immunofluorescence colocalization, cell polarity disruption, PKC inhibition, siRNA knockdown, chemotaxis assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus colocalization with polarity-dependence validation and functional siRNA knockdown, single lab","pmids":["21381019"],"is_preprint":false},{"year":2004,"finding":"Activation of ICAM-3 on human bone marrow endothelial cells by antibody cross-linking reduces electrical resistance of endothelial monolayers and causes loss of cell-cell contacts; cross-linking induces association of moesin (and later ezrin) with ICAM-3, and stimulates production of reactive oxygen species (ROS) that mediate control of endothelial integrity.","method":"Electrical resistance measurements, immunocytochemistry, biochemical pull-down/co-IP of moesin and ezrin, ROS detection","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay (resistance measurement) linked to molecular association (ERM proteins) and ROS signaling, single lab","pmids":["14726630"],"is_preprint":false}],"current_model":"ICAM-3 (CD50) is a five-domain IgSF cell adhesion molecule constitutively expressed on all resting leukocytes that functions as a ligand for LFA-1 (CD11a/CD18) through domain 1 residues on both the ABED and GFC faces, and also binds αdβ2 integrin and DC-SIGN (via Lewis x glycans); it acts as a co-stimulatory and outside-in signaling molecule on T cells (engaging p56lck, p59fyn, Ca2+ flux, PKC, and PI3K-AKT pathways), undergoes proteolytic shedding from activated neutrophils, localizes to the T cell uropod at the APC contact initiation zone, participates in apoptotic cell recognition and clearance by macrophages via a domain 1-2-dependent tethering interaction, and drives cancer cell migration, invasion, stemness, and metastasis through an intracellular YLPL-Src-AKT-CREB-MMP axis and a LFA-1-ICAM-3-ERM mechanical tension mechanism; its expression is transcriptionally repressed by RUNX3 during monocyte-to-macrophage differentiation."},"narrative":{"mechanistic_narrative":"ICAM-3 (CD50/ICAM-R) is a five-domain immunoglobulin-superfamily adhesion molecule constitutively expressed on resting leukocytes that serves as a principal ligand for the integrin LFA-1 (CD11a/CD18) and acts as a bidirectional signaling and adhesion hub at leukocyte contact sites [PMID:1448173, PMID:1448174, PMID:7905020]. LFA-1 binding is mediated by the N-terminal Ig-like domain 1, which is necessary and sufficient, through residues clustering on both the ABED and GFC faces — a more extensive footprint than that used by ICAM-1 — and is engaged through the LFA-1 α-subunit I domain in a cation-dependent manner [PMID:8798624, PMID:9686599, PMID:7518468, PMID:9271587]. Beyond LFA-1, ICAM-3 is preferentially bound by the αdβ2 integrin and, via Lewis-x and high-mannose glycans on its complex-type N-linked oligosaccharides, by the dendritic-cell lectin DC-SIGN to mediate early DC–T-cell adhesion [PMID:8777714, PMID:10721994, PMID:17145745, PMID:11179968]. ICAM-3 engagement triggers outside-in signaling: it associates with the Src-family kinases p56lck and p59fyn, drives calcium flux and tyrosine phosphorylation under CD45 regulation, raises β1/β2 integrin avidity, and co-stimulates T-cell proliferation and chemokine secretion from monocytes and neutrophils [PMID:7515097, PMID:7520448, PMID:7515813, PMID:8223855, PMID:9605163, PMID:9834117]. The molecule polarizes to the T-cell uropod and clusters at the APC contact-initiation zone, positioning it for the earliest scanning phase of immune synapse formation, and is shed proteolytically from activated neutrophils and lymphocytes to yield a circulating soluble form [PMID:7525599, PMID:11812993, PMID:7525295, PMID:7876564]. On apoptotic leukocytes, domain 1–2 of ICAM-3 switches to an alternative recognition activity that tethers dying cells and their microparticles to macrophage CD14 to drive chemoattraction and efferocytosis [PMID:10352301, PMID:22117198, PMID:23775590]. Its leukocyte-restricted promoter is repressed by RUNX3 during monocyte-to-macrophage differentiation [PMID:22479382]. In cancer cells ICAM-3 promotes migration, invasion, stemness and metastasis through an intracellular YLPL-Src-AKT-CREB-MMP axis and an LFA-1–ICAM-3–ERM mechanical-tension mechanism [PMID:19956847, PMID:29477378, PMID:29729315].","teleology":[{"year":1992,"claim":"Established the molecular identity of ICAM-3 as an IgSF adhesion molecule and a third constitutive LFA-1 ligand, defining a leukocyte-restricted adhesion receptor distinct from endothelial ICAMs.","evidence":"expression cloning, cell adhesion and antibody-blocking assays across two independent papers","pmids":["1448173","1448174"],"confidence":"High","gaps":["Binding interface on ICAM-3 not yet mapped","Cytoplasmic signaling function unknown"]},{"year":1993,"claim":"Showed ICAM-3 is not merely an adhesive ligand but an active regulator that, when engaged, drives LFA-1/ICAM-1-dependent aggregation and co-stimulates proliferation, and confirmed CDw50/ICAM-3 identity.","evidence":"adhesion on purified ICAM-3, mAb blocking, immunofluorescence, proliferation assays, protein sequencing","pmids":["7901223","8325327"],"confidence":"High","gaps":["Signaling intermediates downstream of engagement undefined","Mechanism of integrin avidity modulation unclear"]},{"year":1994,"claim":"Localized the LFA-1 binding site to ICAM-3 domain 1 by systematic mutagenesis and structural EM, defining conserved versus specificity-conferring residues and the reciprocal LFA-1 I domain as the binding partner.","evidence":"domain-deletion chimeras, 45 point mutants, mAb epitope mapping, electron microscopy","pmids":["8798624","7531103","7518468"],"confidence":"High","gaps":["Co-crystal structure absent","Conformational requirements on LFA-1 not fully resolved"]},{"year":1994,"claim":"Defined ICAM-3 outside-in signaling, linking engagement to Src-family kinases, calcium flux, CD45-regulated tyrosine phosphorylation, and integrin avidity upregulation.","evidence":"anti-CD50 cross-linking, Ca2+ measurement, phosphotyrosine co-IP and in vitro kinase assays, CD45 inhibitor and tyrosine-kinase inhibitor studies, adhesion assays","pmids":["7515097","7520448","7515813","8223855","1730238"],"confidence":"High","gaps":["Direct adaptor coupling p56lck/p59fyn to ICAM-3 cytoplasmic tail not defined","Whether phosphorylation is on ICAM-3 itself or associated proteins not fully resolved"]},{"year":1994,"claim":"Defined ICAM-3 receptor specificity and ligand promiscuity — it binds the new αdβ2 integrin preferentially over ICAM-1 but is not a ligand for Mac-1 or p150,95 — narrowing the set of relevant integrin partners.","evidence":"cDNA cloning of αd, transfectant adhesion comparisons, bidirectional purified-protein adhesion assays","pmids":["8777714","7737271"],"confidence":"High","gaps":["Physiological context of αdβ2–ICAM-3 binding unclear","Affinity hierarchy among integrin ligands not quantified"]},{"year":1994,"claim":"Demonstrated that ICAM-3 surface levels are dynamically controlled by proteolytic shedding from activated neutrophils and lymphocytes, generating a circulating soluble form.","evidence":"internalization assays ruling out endocytosis, protease inhibition, detection of shed protein in supernatant and plasma, ELISA/immunoblot size comparison","pmids":["7525295","7876564"],"confidence":"High","gaps":["Identity of the responsible protease not established","Functional role of soluble ICAM-3 in vivo unclear"]},{"year":1998,"claim":"Refined the LFA-1 binding footprint, showing it spans both ABED and GFC faces of domain 1 — more extensive and partly distinct from ICAM-1 — explaining selective ligand engagement.","evidence":"18-residue site-directed mutagenesis with LFA-1 adhesion assays","pmids":["9686599"],"confidence":"High","gaps":["No atomic-resolution structure of the complex"]},{"year":1998,"claim":"Established epitope-specific outside-in signaling on myeloid cells, with domain-1-directed engagement driving chemokine secretion, spreading, and β2-integrin-dependent aggregation through tyrosine and PKC kinases.","evidence":"Fab/F(ab')2 fragment engagement controls, chemokine ELISA, kinase and cytoskeleton assays, anti-β2 blocking","pmids":["9605163","9834117"],"confidence":"High","gaps":["Direct cytoplasmic effectors transducing the signal undefined","Why different domain-1 mAbs give opposite effects (HP2/19 vs CAL3.10) mechanistically unexplained"]},{"year":1999,"claim":"Revealed a context switch in ICAM-3 function: on apoptotic leukocytes domain 1 changes binding preference from LFA-1 to a macrophage CD14-dependent recognition activity for clearance of dying cells.","evidence":"mAb blockade of candidate macrophage receptors, ICAM-3 transfection into non-leukocytes, multiple apoptosis stimuli","pmids":["10352301"],"confidence":"High","gaps":["Molecular basis of the apoptotic conformational/glycan change not defined","Direct CD14–ICAM-3 binding not biochemically reconstituted"]},{"year":2000,"claim":"Identified DC-SIGN as a high-affinity ICAM-3 receptor mediating transient DC–T-cell adhesion required for primary immune response initiation, extending ICAM-3 ligand repertoire beyond integrins.","evidence":"DC-SIGN expression identification, binding assays, anti-DC-SIGN inhibition of DC–T adhesion and proliferation","pmids":["10721994"],"confidence":"High","gaps":["Carbohydrate basis of binding not yet defined at this stage"]},{"year":2001,"claim":"Resolved the glycan structures of ICAM-3 and identified the high-mannose component as a candidate DC-SIGN ligand, linking glycosylation to lectin recognition.","evidence":"hydrazinolysis, lectin chromatography, glycosidase digestion, methylation analysis","pmids":["11179968"],"confidence":"High","gaps":["Functional contribution of each glycan species to DC-SIGN binding not directly tested here"]},{"year":2002,"claim":"Placed ICAM-3 at the spatiotemporal start of immune-synapse formation, showing it clusters at the T-cell–APC contact-initiation zone before antigen recognition and supports the scanning phase.","evidence":"time-lapse live-cell imaging, antibody blocking of conjugate formation, early signaling and cytoskeletal readouts","pmids":["11812993","7525599"],"confidence":"High","gaps":["Cytoskeletal adaptors anchoring ICAM-3 at the uropod/contact zone not identified here"]},{"year":2006,"claim":"Defined the carbohydrate determinant of DC-SIGN recognition as Lewis-x on myeloid-cell ICAM-3, synthesized primarily by FUT9, refining the glycan-dependent lectin interaction.","evidence":"binding with native ICAM-3, MALDI-TOF glycan identification, FUT isoform cotransfection, Lewis-x mAb staining","pmids":["17145745","14970226"],"confidence":"High","gaps":["Lymphocyte-derived ICAM-3 binds DC-SIGN by a distinct (mannose) determinant not fully dissected"]},{"year":2011,"claim":"Connected ICAM-3 to efferocytosis machinery, showing apoptotic-cell-derived ICAM-3-bearing microparticles act as macrophage chemoattractants and that domain 1–2 tethers dying cells to phagocytes; also identified Kidins220/ARMS as a uropod-associated partner restraining migration.","evidence":"ICAM-3-deficient apoptotic cells, blocking mAbs, chemotaxis/phagocytosis assays, microparticle isolation; co-IP and PKC-regulated colocalization for Kidins220","pmids":["22117198","21381019"],"confidence":"High","gaps":["Receptor on macrophages capturing microparticle ICAM-3 not fully defined","Kidins220–ICAM-3 interaction is single-lab co-IP"]},{"year":2012,"claim":"Identified RUNX3 as a negative transcriptional regulator of the leukocyte-restricted ICAM-3 promoter, explaining the downregulation of ICAM-3 during monocyte-to-macrophage differentiation.","evidence":"promoter-reporter assays, ChIP occupancy, RUNX-site mutagenesis, RUNX3 siRNA, differentiation tracking","pmids":["22479382"],"confidence":"High","gaps":["Activating transcription factors driving constitutive leukocyte expression less defined"]},{"year":2018,"claim":"Extended ICAM-3 function into cancer, defining an intracellular YLPL–Src–AKT axis driving stemness via SOX2/OCT4 and an LFA-1–ICAM-3–ERM mechanical-tension mechanism driving metastasis, building on the earlier AKT–CREB–MMP migration pathway.","evidence":"shRNA knockdown, Src/ERM co-IP with intracellular domain, domain mutants, pathway inhibitors, xenografts, Lifitegrast/LFA-1 blockade; stable OE migration/invasion assays","pmids":["29477378","29729315","19956847"],"confidence":"Medium","gaps":["Single-lab studies for each cancer mechanism","YLPL–Src and ERM associations not structurally resolved","Direct in vivo clinical relevance unestablished"]},{"year":null,"claim":"How the same domain-1 surface and cytoplasmic tail are toggled between LFA-1 adhesion, apoptotic CD14 recognition, and intracellular Src/ERM engagement — and which proteases and conformational switches govern these transitions — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No atomic structure of ICAM-3 in complex with any partner","Shedding protease unidentified","Mechanism of apoptosis-induced functional switch undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,7,2,23]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[9,21,22,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,10,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,14,28]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,24,23,33]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,21,22,35]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,2,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[34,35,36]}],"complexes":[],"partners":["ITGAL","ITGB2","ITGAD","CD209","LCK","FYN","EZR","KIDINS220"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P32942","full_name":"Intercellular adhesion molecule 3","aliases":["CDw50","ICAM-R"],"length_aa":547,"mass_kda":59.5,"function":"Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring apoptotic neutrophil phagocytosis by macrophages (PubMed:1448173, PubMed:1448174, PubMed:23775590, PubMed:8325327, PubMed:8459213). Is also a ligand for integrin ITGAD/ITGB2 (PubMed:8777714). Ligand of CD209 on dendritic cells (DC) through an integrin-independent mechanism that requires Ca(2+) and that forms a first contact between DC and resting T cell, facilitating the downstream DC-T cell clustering process and DC-induced proliferation of resting T Cells (PubMed:10721994)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P32942/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ICAM3","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ICAM3","total_profiled":1310},"omim":[{"mim_id":"614371","title":"DENGUE VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/614371"},{"mim_id":"614088","title":"INTRACELLULAR ADHESION MOLECULE 4; ICAM4","url":"https://www.omim.org/entry/614088"},{"mim_id":"605872","title":"C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M","url":"https://www.omim.org/entry/605872"},{"mim_id":"604672","title":"CD209 ANTIGEN; CD209","url":"https://www.omim.org/entry/604672"},{"mim_id":"602037","title":"RAS HOMOLOG GENE FAMILY, MEMBER H; RHOH","url":"https://www.omim.org/entry/602037"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":167.4},{"tissue":"lymphoid tissue","ntpm":88.8}],"url":"https://www.proteinatlas.org/search/ICAM3"},"hgnc":{"alias_symbol":["CDW50","ICAM-R","CD50"],"prev_symbol":[]},"alphafold":{"accession":"P32942","domains":[{"cath_id":"2.60.40.10","chopping":"33-113","consensus_level":"high","plddt":92.563,"start":33,"end":113},{"cath_id":"2.60.40.10","chopping":"118-215","consensus_level":"high","plddt":95.4077,"start":118,"end":215},{"cath_id":"2.60.40.10","chopping":"223-311","consensus_level":"high","plddt":95.2322,"start":223,"end":311},{"cath_id":"2.60.40.10","chopping":"317-397","consensus_level":"high","plddt":94.5023,"start":317,"end":397},{"cath_id":"2.60.40.10","chopping":"404-479","consensus_level":"high","plddt":91.5886,"start":404,"end":479}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32942","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32942-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32942-F1-predicted_aligned_error_v6.png","plddt_mean":87.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ICAM3","jax_strain_url":"https://www.jax.org/strain/search?query=ICAM3"},"sequence":{"accession":"P32942","fasta_url":"https://rest.uniprot.org/uniprotkb/P32942.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32942/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32942"}},"corpus_meta":[{"pmid":"10721994","id":"PMC_10721994","title":"Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10721994","citation_count":1340,"is_preprint":false},{"pmid":"12783086","id":"PMC_12783086","title":"Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses.","date":"2003","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/12783086","citation_count":383,"is_preprint":false},{"pmid":"1448173","id":"PMC_1448173","title":"Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1448173","citation_count":322,"is_preprint":false},{"pmid":"8777714","id":"PMC_8777714","title":"A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8777714","citation_count":224,"is_preprint":false},{"pmid":"1448174","id":"PMC_1448174","title":"Cloning and characterization of a new intercellular adhesion molecule ICAM-R.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1448174","citation_count":198,"is_preprint":false},{"pmid":"7905020","id":"PMC_7905020","title":"Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7905020","citation_count":156,"is_preprint":false},{"pmid":"7901223","id":"PMC_7901223","title":"ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7901223","citation_count":150,"is_preprint":false},{"pmid":"8129777","id":"PMC_8129777","title":"Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis.","date":"1994","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/8129777","citation_count":133,"is_preprint":false},{"pmid":"10352301","id":"PMC_10352301","title":"Macrophage recognition of ICAM-3 on apoptotic leukocytes.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10352301","citation_count":125,"is_preprint":false},{"pmid":"11812993","id":"PMC_11812993","title":"Role of ICAM-3 in the initial interaction of T lymphocytes and APCs.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11812993","citation_count":123,"is_preprint":false},{"pmid":"8568591","id":"PMC_8568591","title":"The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium.","date":"1995","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8568591","citation_count":119,"is_preprint":false},{"pmid":"12021323","id":"PMC_12021323","title":"Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission.","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12021323","citation_count":103,"is_preprint":false},{"pmid":"7520448","id":"PMC_7520448","title":"Induction of tyrosine phosphorylation during ICAM-3 and LFA-1-mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7520448","citation_count":98,"is_preprint":false},{"pmid":"21098395","id":"PMC_21098395","title":"Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFN{gamma}: role of CD18, ICAM-1, and ICAM-3.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21098395","citation_count":89,"is_preprint":false},{"pmid":"22117198","id":"PMC_22117198","title":"Apoptotic cell-derived ICAM-3 promotes both macrophage chemoattraction to and tethering of apoptotic cells.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22117198","citation_count":88,"is_preprint":false},{"pmid":"8223855","id":"PMC_8223855","title":"ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8223855","citation_count":88,"is_preprint":false},{"pmid":"19230080","id":"PMC_19230080","title":"Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN).","date":"2009","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/19230080","citation_count":86,"is_preprint":false},{"pmid":"17001080","id":"PMC_17001080","title":"The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin).","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17001080","citation_count":85,"is_preprint":false},{"pmid":"7518468","id":"PMC_7518468","title":"Involvement of the \"I\" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7518468","citation_count":82,"is_preprint":false},{"pmid":"15111305","id":"PMC_15111305","title":"Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15111305","citation_count":78,"is_preprint":false},{"pmid":"19956847","id":"PMC_19956847","title":"ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19956847","citation_count":75,"is_preprint":false},{"pmid":"10931137","id":"PMC_10931137","title":"Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10931137","citation_count":75,"is_preprint":false},{"pmid":"7525599","id":"PMC_7525599","title":"ICAM-3 regulates lymphocyte morphology and integrin-mediated T cell interaction with endothelial cell and extracellular matrix ligands.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7525599","citation_count":73,"is_preprint":false},{"pmid":"20080962","id":"PMC_20080962","title":"Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20080962","citation_count":72,"is_preprint":false},{"pmid":"7515097","id":"PMC_7515097","title":"CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization and tyrosine phosphorylation through p59fyn and p56lck in Jurkat T cell line.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7515097","citation_count":65,"is_preprint":false},{"pmid":"16134084","id":"PMC_16134084","title":"Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16134084","citation_count":61,"is_preprint":false},{"pmid":"9271587","id":"PMC_9271587","title":"The lymphocyte function-associated antigen 1 I domain is a transient binding module for intercellular adhesion molecule (ICAM)-1 and ICAM-3 in hydrodynamic flow.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9271587","citation_count":57,"is_preprint":false},{"pmid":"7515813","id":"PMC_7515813","title":"Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in beta 1 and beta 2 integrin function.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7515813","citation_count":54,"is_preprint":false},{"pmid":"9174593","id":"PMC_9174593","title":"RANTES stimulation of T lymphocyte adhesion and activation: role for LFA-1 and ICAM-3.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9174593","citation_count":54,"is_preprint":false},{"pmid":"7542573","id":"PMC_7542573","title":"Adhesion molecules intercellular adhesion molecule-1 (ICAM-1), ICAM-3 and B7 are not expressed by epithelium in normal or inflamed colon.","date":"1995","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7542573","citation_count":53,"is_preprint":false},{"pmid":"22205703","id":"PMC_22205703","title":"Retagging identifies dendritic cell-specific intercellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN) protein as a novel receptor for a major allergen from house dust mite.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22205703","citation_count":50,"is_preprint":false},{"pmid":"14970226","id":"PMC_14970226","title":"DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14970226","citation_count":50,"is_preprint":false},{"pmid":"7516162","id":"PMC_7516162","title":"Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium. Comparison with other adhesion molecules.","date":"1994","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/7516162","citation_count":45,"is_preprint":false},{"pmid":"7916296","id":"PMC_7916296","title":"Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7916296","citation_count":44,"is_preprint":false},{"pmid":"7836774","id":"PMC_7836774","title":"Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7836774","citation_count":44,"is_preprint":false},{"pmid":"10427988","id":"PMC_10427988","title":"Co-stimulation of T cells results in distinct IL-10 and TNF-alpha cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10427988","citation_count":43,"is_preprint":false},{"pmid":"10374960","id":"PMC_10374960","title":"Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7.","date":"1999","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/10374960","citation_count":43,"is_preprint":false},{"pmid":"10725740","id":"PMC_10725740","title":"Shear and time-dependent changes in Mac-1, LFA-1, and ICAM-3 binding regulate neutrophil homotypic adhesion.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10725740","citation_count":42,"is_preprint":false},{"pmid":"8798624","id":"PMC_8798624","title":"Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798624","citation_count":41,"is_preprint":false},{"pmid":"8325327","id":"PMC_8325327","title":"CDw50 and ICAM-3: two names for the same molecule.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8325327","citation_count":40,"is_preprint":false},{"pmid":"7525295","id":"PMC_7525295","title":"Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7525295","citation_count":40,"is_preprint":false},{"pmid":"29477378","id":"PMC_29477378","title":"ICAM3 mediates inflammatory signaling to promote cancer cell stemness.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29477378","citation_count":37,"is_preprint":false},{"pmid":"23775590","id":"PMC_23775590","title":"Novel role of ICAM3 and LFA-1 in the clearance of apoptotic neutrophils by human macrophages.","date":"2013","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/23775590","citation_count":37,"is_preprint":false},{"pmid":"18076668","id":"PMC_18076668","title":"Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation.","date":"2007","source":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18076668","citation_count":37,"is_preprint":false},{"pmid":"16215763","id":"PMC_16215763","title":"The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment.","date":"2005","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/16215763","citation_count":37,"is_preprint":false},{"pmid":"7876557","id":"PMC_7876557","title":"CD50 (ICAM-3) is phosphorylated on tyrosine and is associated with tyrosine kinase activity in human neutrophils.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7876557","citation_count":35,"is_preprint":false},{"pmid":"18073208","id":"PMC_18073208","title":"Structural requirements for multimerization of the pathogen receptor dendritic cell-specific ICAM3-grabbing non-integrin (CD209) on the cell surface.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18073208","citation_count":34,"is_preprint":false},{"pmid":"15880373","id":"PMC_15880373","title":"Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15880373","citation_count":32,"is_preprint":false},{"pmid":"22479382","id":"PMC_22479382","title":"RUNX3 regulates intercellular adhesion molecule 3 (ICAM-3) expression during macrophage differentiation and monocyte extravasation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479382","citation_count":31,"is_preprint":false},{"pmid":"8132828","id":"PMC_8132828","title":"Cellular distribution of human leucocyte adhesion molecule ICAM-3.","date":"1994","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8132828","citation_count":31,"is_preprint":false},{"pmid":"11739669","id":"PMC_11739669","title":"Binding of LFA-1 (CD11a) to intercellular adhesion molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) triggers transmigration of human immunodeficiency virus type 1-infected monocytes through mucosal epithelial cells.","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11739669","citation_count":30,"is_preprint":false},{"pmid":"8214000","id":"PMC_8214000","title":"ICAM-3 expression on endothelium in lymphoid malignancy.","date":"1993","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8214000","citation_count":30,"is_preprint":false},{"pmid":"7531103","id":"PMC_7531103","title":"LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids.","date":"1994","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/7531103","citation_count":30,"is_preprint":false},{"pmid":"7875209","id":"PMC_7875209","title":"Epitope mapping and functional properties of anti-intercellular adhesion molecule-3 (CD50) monoclonal antibodies.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7875209","citation_count":29,"is_preprint":false},{"pmid":"7876564","id":"PMC_7876564","title":"Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation. Present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7876564","citation_count":29,"is_preprint":false},{"pmid":"19029201","id":"PMC_19029201","title":"Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages.","date":"2008","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19029201","citation_count":29,"is_preprint":false},{"pmid":"17570115","id":"PMC_17570115","title":"Association of ICAM3 genetic variant with severe acute respiratory syndrome.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17570115","citation_count":28,"is_preprint":false},{"pmid":"17145745","id":"PMC_17145745","title":"DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis x residues.","date":"2006","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17145745","citation_count":28,"is_preprint":false},{"pmid":"7737271","id":"PMC_7737271","title":"Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and p150,95.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7737271","citation_count":27,"is_preprint":false},{"pmid":"27552332","id":"PMC_27552332","title":"Increased Cell Adhesion Molecules, PECAM-1, ICAM-3, or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease.","date":"2017","source":"Journal of clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27552332","citation_count":26,"is_preprint":false},{"pmid":"9605163","id":"PMC_9605163","title":"Coengagement of ICAM-3 and Fc receptors induces chemokine secretion and spreading by myeloid leukocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9605163","citation_count":24,"is_preprint":false},{"pmid":"10189240","id":"PMC_10189240","title":"ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas.","date":"1999","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10189240","citation_count":23,"is_preprint":false},{"pmid":"9766501","id":"PMC_9766501","title":"Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9766501","citation_count":23,"is_preprint":false},{"pmid":"29729315","id":"PMC_29729315","title":"ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29729315","citation_count":22,"is_preprint":false},{"pmid":"11179968","id":"PMC_11179968","title":"Structural study of N-linked oligosaccharides of human intercellular adhesion molecule-3 (CD50).","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11179968","citation_count":22,"is_preprint":false},{"pmid":"18678668","id":"PMC_18678668","title":"Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50.","date":"2008","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18678668","citation_count":21,"is_preprint":false},{"pmid":"9131010","id":"PMC_9131010","title":"Antibodies to the beta 1-integrin chain, CD44, or ICAM-3 stimulate adhesion of blast colony-forming cells and may inhibit their growth.","date":"1997","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9131010","citation_count":21,"is_preprint":false},{"pmid":"29662482","id":"PMC_29662482","title":"Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29662482","citation_count":19,"is_preprint":false},{"pmid":"7544645","id":"PMC_7544645","title":"B-cell homotypic adhesion through exon-A restricted epitopes of CD45 involves LFA-1/ICAM-1, ICAM-3 interactions, and induces coclustering of CD45 and LFA-1.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7544645","citation_count":19,"is_preprint":false},{"pmid":"10891379","id":"PMC_10891379","title":"Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10891379","citation_count":19,"is_preprint":false},{"pmid":"14726630","id":"PMC_14726630","title":"ICAM-3 activation modulates cell-cell contacts of human bone marrow endothelial cells.","date":"2004","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/14726630","citation_count":18,"is_preprint":false},{"pmid":"7851905","id":"PMC_7851905","title":"The human intercellular adhesion molecule 3 (ICAM3) gene is located in the 19p13.2-p13.3 region, close to the ICAM1 gene.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7851905","citation_count":18,"is_preprint":false},{"pmid":"10688433","id":"PMC_10688433","title":"Regulation of ICAM-3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone.","date":"1999","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/10688433","citation_count":17,"is_preprint":false},{"pmid":"7539471","id":"PMC_7539471","title":"Intercellular adhesion molecule-3 (CD50) on human epidermal Langerhans cells participates in T-cell activation.","date":"1995","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7539471","citation_count":15,"is_preprint":false},{"pmid":"11261782","id":"PMC_11261782","title":"Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion--evidence for retinoid signaling pathways in the mast cell lineage.","date":"2001","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11261782","citation_count":15,"is_preprint":false},{"pmid":"9834117","id":"PMC_9834117","title":"Engagement of ICAM-3 activates polymorphonuclear leukocytes: aggregation without degranulation or beta 2 integrin recruitment.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9834117","citation_count":15,"is_preprint":false},{"pmid":"9008304","id":"PMC_9008304","title":"Stimulation through CD50 (ICAM-3) induces both activation and programmed cell death of human thymocytes.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9008304","citation_count":14,"is_preprint":false},{"pmid":"9218600","id":"PMC_9218600","title":"CD50 monoclonal antibodies inhibit neutrophil activation.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9218600","citation_count":14,"is_preprint":false},{"pmid":"7482494","id":"PMC_7482494","title":"CD50 (intercellular adhesion molecule-3) is expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets.","date":"1995","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/7482494","citation_count":14,"is_preprint":false},{"pmid":"10706734","id":"PMC_10706734","title":"CD4+ T cell and eosinophil adhesion is mediated by specific ICAM-3 ligation and results in eosinophil activation.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706734","citation_count":14,"is_preprint":false},{"pmid":"9828136","id":"PMC_9828136","title":"Mapping of the ICAM-5 (telencephalin) gene, a neuronal member of the ICAM family, to a location between ICAM-1 and ICAM-3 on human chromosome 19p13.2.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9828136","citation_count":14,"is_preprint":false},{"pmid":"1730238","id":"PMC_1730238","title":"Effect of protein kinase C activators on the phosphorylation and the surface expression of the CDw50 leukocyte antigen.","date":"1992","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1730238","citation_count":13,"is_preprint":false},{"pmid":"21381019","id":"PMC_21381019","title":"The neuronal protein Kidins220/ARMS associates with ICAM-3 and other uropod components and regulates T-cell motility.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21381019","citation_count":13,"is_preprint":false},{"pmid":"24177012","id":"PMC_24177012","title":"ICAM-3 endows anticancer drug resistance against microtubule-damaging agents via activation of the ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24177012","citation_count":13,"is_preprint":false},{"pmid":"10685862","id":"PMC_10685862","title":"Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.","date":"2000","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/10685862","citation_count":13,"is_preprint":false},{"pmid":"9686599","id":"PMC_9686599","title":"The leukocyte function-associated antigen-1 (LFA-1)-binding site on ICAM-3 comprises residues on both faces of the first immunoglobulin domain.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9686599","citation_count":13,"is_preprint":false},{"pmid":"11493756","id":"PMC_11493756","title":"CD50 and CD62L adhesion receptor expression on naive (CD45RA+) and memory (CD45RO+) T lymphocytes in the elderly.","date":"2000","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11493756","citation_count":12,"is_preprint":false},{"pmid":"11083511","id":"PMC_11083511","title":"CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis.","date":"2000","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/11083511","citation_count":11,"is_preprint":false},{"pmid":"8546991","id":"PMC_8546991","title":"Expression of ICAM-3/CD50 in normal and diseased skin.","date":"1995","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8546991","citation_count":10,"is_preprint":false},{"pmid":"10380912","id":"PMC_10380912","title":"ICAM-3 (CD50) cross-linking augments signaling in CD3-activated peripheral human T lymphocytes.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10380912","citation_count":10,"is_preprint":false},{"pmid":"8946680","id":"PMC_8946680","title":"Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors.","date":"1996","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8946680","citation_count":9,"is_preprint":false},{"pmid":"8429685","id":"PMC_8429685","title":"Isolation and characterisation of a CDw50 negative Jurkat T-cell line variant (PPL.1).","date":"1993","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/8429685","citation_count":8,"is_preprint":false},{"pmid":"31083610","id":"PMC_31083610","title":"ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.","date":"2019","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31083610","citation_count":8,"is_preprint":false},{"pmid":"7782098","id":"PMC_7782098","title":"Expression of ICAM-3 on human epidermal dendritic cells.","date":"1995","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/7782098","citation_count":8,"is_preprint":false},{"pmid":"10626904","id":"PMC_10626904","title":"ICAM-3 (CD50) is expressed by human mast cells: induction of homotypic mast cell aggregation via ICAM-3.","date":"1999","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/10626904","citation_count":7,"is_preprint":false},{"pmid":"9929740","id":"PMC_9929740","title":"Stimulation through CD50 preferentially induces apoptosis of TCR1+ human peripheral blood lymphocytes.","date":"1998","source":"Cell adhesion and communication","url":"https://pubmed.ncbi.nlm.nih.gov/9929740","citation_count":7,"is_preprint":false},{"pmid":"17434553","id":"PMC_17434553","title":"ICAM-3 influences human immunodeficiency virus type 1 replication in CD4(+) T cells independent of DC-SIGN-mediated transmission.","date":"2007","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/17434553","citation_count":7,"is_preprint":false},{"pmid":"15890347","id":"PMC_15890347","title":"ICAM-3, a ligand for DC-SIGN, was duplicated from ICAM-1 in mammalian evolution, but was lost in the rodent genome.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15890347","citation_count":6,"is_preprint":false},{"pmid":"17962491","id":"PMC_17962491","title":"An intercellular adhesion molecule-3 (ICAM-3) -grabbing nonintegrin (DC-SIGN) efficiently blocks HIV viral budding.","date":"2007","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17962491","citation_count":6,"is_preprint":false},{"pmid":"7576578","id":"PMC_7576578","title":"Expression of the intercellular adhesion molecule-3 (ICAM-3) in human renal tissue with relation to kidney transplants and various inflammatory diseases.","date":"1995","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/7576578","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52583,"output_tokens":10729,"usd":0.159342,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21328,"output_tokens":5520,"usd":0.12232,"stage2_stop_reason":"end_turn"},"total_usd":0.281662,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"ICAM-3 (ICAM-R/CD50) is a member of the immunoglobulin superfamily with five extracellular Ig-like domains that binds LFA-1 (CD11a/CD18), functioning as a third ligand for LFA-1; it is constitutively expressed on all resting leukocytes but not on resting or cytokine-activated endothelial cells.\",\n      \"method\": \"Expression cloning of cDNA, cell adhesion assays, antibody blocking experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two independent molecular cloning papers (PMID:1448173 and PMID:1448174) both established LFA-1 binding by direct adhesion assay and antibody blockade, replicated across labs\",\n      \"pmids\": [\"1448173\", \"1448174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ICAM-3 (CDw50) becomes phosphorylated on serine residues upon stimulation with protein kinase C activators (phorbol esters, mezerein) and by lymphocyte activation agents (ConA, PHA, anti-CD3 cross-linking); this phosphorylation is rapid, dose-dependent, and inhibited by PKC inhibitors staurosporine and H-7, but does not alter surface expression levels.\",\n      \"method\": \"Radiolabeling with 32P-orthophosphate, phosphoamino acid analysis, PKC inhibitor assays, flow cytometry\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical phosphorylation assays with pharmacological inhibitors in a single lab, multiple cell types tested\",\n      \"pmids\": [\"1730238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"ICAM-3 regulates the LFA-1/ICAM-1 adhesion pathway: engagement of ICAM-3 by activating anti-ICAM-3 mAb (HP2/19, epitope A) triggers LFA-1/ICAM-1-dependent T lymphoblast homotypic aggregation, increases T cell attachment to ICAM-1, and co-stimulates T lymphocyte proliferation with anti-CD3. ICAM-3 localizes to cellular uropods during aggregation, distinct from LFA-1 and ICAM-1 at intercellular boundaries.\",\n      \"method\": \"T cell adhesion assays on purified ICAM-3 surfaces, mAb blocking with anti-LFA-1 and anti-ICAM-1, immunofluorescence microscopy, proliferation assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal assays (adhesion, aggregation, imaging, proliferation) in a single study, replicated functionally by other labs\",\n      \"pmids\": [\"7901223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CDw50 and ICAM-3 are the same glycoprotein (120 kDa surface molecule); identity established by immunochemical, functional, and protein sequencing studies.\",\n      \"method\": \"Protein sequencing, immunochemical cross-reactivity, functional adhesion assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct protein sequencing combined with functional and immunochemical validation\",\n      \"pmids\": [\"8325327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 resides in Ig-like domain 1, which is necessary and sufficient for LFA-1 binding; domain deletion and chimera analysis identified five residues (Asn23, Ser25, Glu37, Phe54, Gln75) that contribute to the binding site, predicted to cluster on the BED face and C/E strands of domain 1 by molecular modeling.\",\n      \"method\": \"Domain deletion mutants, ICAM-3/CD21 chimeras, site-directed mutagenesis (45 point mutants), LFA-1 adhesion assays, epitope mapping with 17 mAbs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis with 45 point mutants combined with domain-deletion chimeras and multiple mAb epitope mapping in a single rigorous study\",\n      \"pmids\": [\"8798624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 engagement activates ICAM-3-independent (LFA-1/ICAM-1-independent) cell aggregation in JM T cells and HAFSA B cells; this aggregation involves tyrosine phosphorylation and is regulated by the CD45 tyrosine phosphatase — anti-CD45 mAbs and tyrosine kinase inhibitors abolish ICAM-3-induced aggregation. Tyrosine-phosphorylated proteins (125, 70, 38 kDa) accumulate at intercellular boundaries upon ICAM-3 or LFA-1 engagement.\",\n      \"method\": \"mAb blocking assays, tyrosine kinase inhibitors (herbimycin A), CD45 inhibitors, immunofluorescence, Western blot of phosphotyrosine\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pharmacological inhibitors, blocking antibodies, immunofluorescence, Western blot) in one study, replicated in multiple cell lines\",\n      \"pmids\": [\"7520448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 engagement by activating mAb (HP2/19) enhances T lymphoblast adhesion to ICAM-1, VCAM-1, fibronectin fragments (FN40, FN80) via increased LFA-1 and VLA-4/VLA-5 avidity, and induces a dramatic uropod-like morphological change with exclusive redistribution of ICAM-3 to the distal uropod tip, while LFA-1 and VLA-β1 remain distributed over the contact area.\",\n      \"method\": \"Cell adhesion assays, mAb blocking, immunofluorescence microscopy, phorbol ester controls\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional adhesion assays with integrin-specific blocking mAbs and direct imaging, multiple substrates, single lab with extensive controls\",\n      \"pmids\": [\"7525599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Purified ICAM-3 supports LFA-1-dependent T cell adhesion in a temperature- and cation-dependent manner. Combined mAbs to ICAM-1, ICAM-2, and ICAM-3 achieve near-complete inhibition of LFA-1-dependent lymphocyte proliferative responses (PHA, allogeneic cells, specific antigen), suggesting these three molecules account for most or all functional LFA-1 ligands. ICAM-3 also provides a co-stimulatory signal for resting T lymphocyte proliferation.\",\n      \"method\": \"Adhesion assays on purified ICAM-3, mAb blocking of PBL proliferation (PHA, MLR, antigen), T cell co-stimulation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstituted adhesion with purified protein plus systematic mAb blocking across multiple functional assays, replicated across conditions\",\n      \"pmids\": [\"7905020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 is a ligand for αdβ2 (CD11d/CD18), a novel fourth β2 integrin that shows preferential binding to ICAM-3 over ICAM-1.\",\n      \"method\": \"cDNA cloning of αd chain, transfection, cell adhesion assays comparing ICAM-3 vs ICAM-1 binding\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — identification of new integrin with molecular cloning plus direct binding comparison, replicated later by multiple labs\",\n      \"pmids\": [\"8777714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Cross-linking CD50 (ICAM-3) on Jurkat T cells induces calcium mobilization (primarily via extracellular Ca2+ influx) and tyrosine phosphorylation; p56lck and p59fyn protein tyrosine kinases are found in CD50 immunoprecipitates, implicating these Src-family kinases in CD50 signal transduction.\",\n      \"method\": \"Anti-CD50 cross-linking, intracellular Ca2+ measurement, phosphotyrosine immunoprecipitation, in vitro kinase assays, specific antisera co-immunoprecipitation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assays plus co-IP demonstrating physical association of p56lck and p59fyn, multiple methods in a single study\",\n      \"pmids\": [\"7515097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Signaling through CD50 (ICAM-3) increases T lymphocyte adhesion to TNF-stimulated endothelial cells and extracellular matrix proteins by increasing β1 and β2 integrin avidity, without altering surface integrin expression levels.\",\n      \"method\": \"Anti-CD50 mAb stimulation, adhesion to HUVEC and ECM proteins, mAb blocking of β1 and β2 integrins, ICAM-1 transfectant binding, flow cytometry for integrin surface expression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple adhesion substrates and integrin-specific blocking, single lab\",\n      \"pmids\": [\"7515813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The I domain of LFA-1's α subunit contains the binding site for both ICAM-1 and ICAM-3; two I domain mAbs (YTH81.5 and 122.2A5) selectively block ICAM-3 but not ICAM-1 binding, and one I domain mAb (MEM-83) activates binding to ICAM-1 but not ICAM-3, demonstrating that LFA-1 can selectively engage these two highly homologous ligands through the I domain.\",\n      \"method\": \"T cell binding assays to ICAM-1 or ICAM-3-coated plastic, LFA-1 transfected COS cell adhesion assays, mAb epitope mapping to I domain\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematically tested panel of 29 mAbs with two independent cell-based assay formats, I domain epitopes confirmed\",\n      \"pmids\": [\"7518468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 is a co-stimulatory molecule for both resting and activated T lymphocytes: soluble ICAM-3 or anti-ICAM-3 mAbs co-immobilized with sub-optimal anti-CD3 stimulate CD25 and CD69 expression; this activation is blocked by anti-CD18 mAb, implicating LFA-1 (via its β2 chain) as the mediating integrin. Anti-ICAM-3 (but not anti-ICAM-1) co-stimulates resting cord blood T cells.\",\n      \"method\": \"Co-stimulation assays with immobilized ICAM-3 and anti-CD3, flow cytometry for activation markers (CD25, CD69), mAb blocking with anti-CD18\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct blocking with anti-CD18, multiple cell types (resting and activated), single lab\",\n      \"pmids\": [\"8223855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The LFA-1 binding site in ICAM-3 is in the amino-terminal (domain 1) IgSF domain; electron microscopy shows ICAM-3 is a 15 nm straight rod with head-to-tail domain arrangement; residues E37/T38 form a conserved integrin binding site motif also found in ICAM-1 and VCAM-1, while Q75 may confer LFA-1 binding specificity.\",\n      \"method\": \"Electron microscopy, domain deletion mutants, site-directed mutagenesis, mAb blocking adhesion assays\",\n      \"journal\": \"Cell adhesion and communication\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EM structural characterization combined with mutagenesis and functional adhesion assays in a single study\",\n      \"pmids\": [\"7531103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 surface expression on activated neutrophils is rapidly downregulated by a proteolytic shedding mechanism (not internalization): protease inhibitors block PMA-induced downregulation, and ICAM-3 is detected in cell-free supernatants and in plasma (0-296 ng/ml). The remaining ICAM-3 on the neutrophil surface still supports anti-ICAM-3-triggered homotypic aggregation.\",\n      \"method\": \"Immunofluorescence flow cytometry, 125I-labeled mAb internalization assay, immunoprecipitation of supernatants, radioimmunoassay of plasma, protease inhibitor studies\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (internalization assay ruling out endocytosis, protease inhibition, direct detection of shed protein, functional assay) in a single study\",\n      \"pmids\": [\"7525295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-3 is not a ligand for Mac-1 (CD11b/CD18) or p150,95 (CD11c/CD18): purified ICAM-3 from lymphoid cells and neutrophils does not support adhesion of Mac-1- or p150,95-expressing CHO transfectants, and purified Mac-1 does not support adhesion of ICAM-3-expressing L cell transfectants, despite ICAM-3 being well expressed on neutrophils where Mac-1 is abundant.\",\n      \"method\": \"Cell adhesion assays with CHO and L cell transfectants expressing specific integrins, homotypic aggregation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — rigorous negative result using purified proteins and transfectants expressing defined integrins, bidirectional assay\",\n      \"pmids\": [\"7737271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CD50 (ICAM-3) is phosphorylated on tyrosine in human neutrophils (predominantly phosphotyrosine by phosphoamino acid analysis); phosphorylation increases transiently (peak ~1 min) after stimulation with FMLP, PAF, PMA, or calcium ionophore. Tyrosine kinase activity is detected in CD50 immunoprecipitates from solubilized neutrophils.\",\n      \"method\": \"Radiolabeling ecto-kinase assay, phosphoamino acid analysis, immunoprecipitation in vitro kinase assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay in immunoprecipitate with phosphoamino acid analysis, single lab\",\n      \"pmids\": [\"7876557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A circulating/soluble form of ICAM-3 (sCD50) is produced by lymphocytes upon activation (particularly CD3 triggering), is proteolytically cleaved from the cell membrane (apparent MW ~95 kDa vs membrane ~120 kDa by immunoblot), and is detectable in normal human serum; sCD50 levels are elevated in SLE patients and correlate positively with sCD27 levels.\",\n      \"method\": \"Sandwich ELISA, immunoblot of culture supernatants, Northern blot kinetics, flow cytometry for surface expression\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (ELISA, immunoblot, Northern blot) with size comparison suggesting cleavage, single lab\",\n      \"pmids\": [\"7876564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Stimulation through CD50 (ICAM-3) on human thymocytes by mAb cross-linking induces calcium mobilization and CD69 (but not CD25) expression; co-cross-linking with CD45 inhibits calcium mobilization, implicating tyrosine phosphorylation in CD50 signaling. CD50 cross-linking also increases activation-induced cell death of thymocytes.\",\n      \"method\": \"mAb cross-linking, intracellular Ca2+ measurement, co-cross-linking with anti-CD45, flow cytometry for activation markers, apoptosis assays\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional signal transduction assays with CD45 co-cross-linking demonstrating regulatory interaction, single lab\",\n      \"pmids\": [\"9008304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The LFA-1 I domain alone (expressed as GPI-anchored) is sufficient to mediate transient, Mg2+-dependent rolling adhesion on ICAM-1 and ICAM-3 in hydrodynamic flow. MEM-83 (activating I domain mAb) decreased rolling velocity on ICAM-1 but blocked rolling on ICAM-3, demonstrating that ICAM-3 interaction with the I domain is blocked by this conformational change.\",\n      \"method\": \"Stable GPI-anchored I domain expression, flow cell rolling assays on lipid bilayers with purified ICAM-1 or ICAM-3, activating mAb (MEM-83) treatment, divalent cation substitution\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted rolling adhesion assay with defined I domain construct and purified ligands, divalent cation dependency established\",\n      \"pmids\": [\"9271587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The LFA-1 binding site on ICAM-3 domain 1 is more extensive than that of ICAM-1, involving residues on both the ABED face and GFC face; point mutagenesis of 18 residues identified 7 that reduce or abolish LFA-1 adhesion, including 3 on the A strand of the ABED face — a surface not used by ICAM-1 for LFA-1 binding.\",\n      \"method\": \"18-point mutagenesis of domain 1, LFA-1 adhesion assays, functional blocking mAb binding studies\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic site-directed mutagenesis with functional adhesion assays in a single focused study\",\n      \"pmids\": [\"9686599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ICAM-3 engagement on monocytes and neutrophils by domain 1-directed triggering mAbs induces outside-in signaling: monocytes secrete chemokines MIP-1α, IL-8, and MCP-1; neutrophils secrete IL-8; monocytes show dramatic spreading via Fab/F(ab')2 fragments (excluding Fc-mediated effects). Co-engagement of ICAM-3 and Fc receptors (FcγRI or FcγRII) is required for maximal chemokine secretion by monocytes.\",\n      \"method\": \"Immobilized mAb engagement, ELISA for chemokines, Fab/F(ab')2 fragment controls, microscopy of cell spreading\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Fab fragment controls establish direct outside-in signaling, multiple readouts (chemokines, morphology), two cell types\",\n      \"pmids\": [\"9605163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ICAM-3 engagement on PMN (by CAL3.10 mAb binding in the αLβ2 integrin-binding region) activates PMN homotypic aggregation and adhesion via outside-in signaling: β2 integrin-dependent mechanism, activates tyrosine and PKC kinases, and reorganizes the cytoskeleton without causing degranulation or increasing surface β2 integrin expression. A different anti-ICAM-3 mAb (HP2/19) does not activate PMN, demonstrating epitope-specificity.\",\n      \"method\": \"PMN aggregation assays, F(ab')2 fragment controls, anti-β2 integrin blocking, kinase activity assays, cytoskeleton reorganization assays, degranulation assays (elastase release), flow cytometry for β2 integrin expression\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — F(ab')2 fragments confirm direct outside-in signaling, multiple orthogonal readouts with appropriate controls for Fc vs direct signaling\",\n      \"pmids\": [\"9834117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ICAM-3 on the surface of apoptotic leukocytes acquires altered receptor-binding activity: during apoptosis, the first Ig-like domain of ICAM-3 participates in macrophage recognition and phagocytosis of apoptotic cells. ICAM-3 on apoptotic cells switches binding preference from LFA-1 to an alternative macrophage receptor; mAb blockade of macrophage CD14 (but not αvβ3 or αdβ2) inhibited ICAM-3-dependent recognition of apoptotic cells.\",\n      \"method\": \"mAb blocking of macrophage-apoptotic cell interactions, ICAM-3 transfection into non-leukocytes, multiple apoptosis stimuli, domain 1-specific mAb characterization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transfection into non-leukocytes proves sufficiency, systematic mAb blocking of multiple candidate receptors, multiple apoptosis stimuli confirm generality\",\n      \"pmids\": [\"10352301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DC-SIGN, a novel dendritic cell-specific C-type lectin, binds ICAM-3 expressed on resting T cells with high affinity and mediates transient DC-T cell adhesion required for initiation of primary immune responses; antibodies against DC-SIGN inhibit DC-induced proliferation of resting T cells.\",\n      \"method\": \"Identification of DC-SIGN by expression, binding assays, anti-DC-SIGN mAb inhibition of DC-T cell adhesion and T cell proliferation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor identification with functional validation using blocking antibodies and T cell proliferation assays, published in Cell, widely replicated\",\n      \"pmids\": [\"10721994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LFA-1 binding to ICAM-3 (vs ICAM-1 or ICAM-2) produces distinct cytokine profiles in T cells: ICAM-2 and ICAM-3 co-stimulation induces stronger TNF-α secretion, whereas ICAM-1 co-stimulation induces higher IL-10 production, demonstrating that the specific ICAM ligand engaged by LFA-1 differentially shapes the Th1/Th2 cytokine output.\",\n      \"method\": \"T cell co-stimulation assays on immobilized ICAM-1, -2, or -3, cytokine ELISA (GM-CSF, IFN-γ, IL-2, IL-4, IL-5, IL-10, TNF-α), proliferation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic comparison across all three ICAM ligands with multiple cytokine measurements, single lab\",\n      \"pmids\": [\"10427988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"LFA-1 binds ICAM-3 as its primary ligand supporting neutrophil homotypic adhesion at high shear rates (≥800 s-1), while Mac-1 predominates at low shear rates (~100 s-1); ICAM-3 supports LFA-1-mediated homotypic neutrophil aggregation with efficiency varying with shear rate and time post-stimulation.\",\n      \"method\": \"Cone-plate viscometer shear assay, flow cytometry aggregate quantification, mAb blocking of LFA-1, Mac-1, and ICAM-3, collision efficiency modeling\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative flow-based assay with mAb blocking and mathematical modeling, single lab\",\n      \"pmids\": [\"10725740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ICAM-3 N-linked oligosaccharides are predominantly tri- and tetra-antennary complex-type (~6 mol/mol protein) with poly-N-acetyllactosamine chains; a small amount of high-mannose oligosaccharide (6 α-mannose residues) is present, which can serve as a ligand for DC-SIGN.\",\n      \"method\": \"Hydrazinolysis, paper electrophoresis, lectin column chromatography, sequential glycosidase digestion, methylation analysis, structural characterization\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic structural glycan analysis using multiple orthogonal methods (lectin chromatography, exo/endo-glycosidase, methylation analysis) in a single study\",\n      \"pmids\": [\"11179968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ICAM-3 is specifically clustered at the region of the T lymphocyte surface that initiates contact with APCs before antigen recognition (as shown by time-lapse live imaging), and plays a role in T cell-APC conjugate formation, early intracellular signaling, and cytoskeletal rearrangement in the initial APC-scanning phase.\",\n      \"method\": \"Time-lapse live-cell imaging, antibody blocking of T cell-APC conjugate formation, early signaling assays, cytoskeletal rearrangement assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live imaging directly demonstrates polarized ICAM-3 clustering at contact initiation site, functional blocking confirms role, multiple orthogonal readouts\",\n      \"pmids\": [\"11812993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DC-SIGN binds to gp120 in a distinct but overlapping manner compared to ICAM-2 and ICAM-3: recombinant soluble DC-SIGN binds gp120 >100-fold and >50-fold better than ICAM-2-Fc and ICAM-3-Fc, respectively; Asp-367 mutation enhances gp120 binding but diminishes ICAM-2 and ICAM-3 binding, while Gly-346 mutation abrogates gp120 binding but enhances ICAM-2/ICAM-3 binding.\",\n      \"method\": \"Recombinant protein binding assays (ICAM-2-Fc, ICAM-3-Fc, gp120-Fc), alanine-scanning mutagenesis of DC-SIGN, monosaccharide/disaccharide competition, glycan chip analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic alanine-scanning mutagenesis combined with quantitative binding assays and glycan chip analysis identifying residues differentially required for ICAM vs viral ligands\",\n      \"pmids\": [\"14970226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DC-SIGN binds native ICAM-3 isolated from peripheral leukocytes via Lewis x (Lex) carbohydrate residues; ICAM-3 from granulocytes (not lymphocytes) bears Lex residues mediating DC-SIGN binding; FUT IX is the primary fucosyltransferase mediating Lex synthesis on ICAM-3 in myeloid cells, with minor contribution from FUT IV.\",\n      \"method\": \"DC-SIGN binding assays with native ICAM-3, Lewis x mAb staining, MALDI-TOF mass spectrometry for Lex confirmation, cotransfection of FUT isoforms (FUT III, IV, VII, IX) with ICAM-3, flow cytometry\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — MS-confirmed glycan identification combined with FUT cotransfection experiments identifying specific biosynthetic enzyme, cell-type comparison\",\n      \"pmids\": [\"17145745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Apoptotic cell-derived microparticles bearing ICAM-3 potently attract macrophages (chemoattraction) to sites of leukocyte cell death; ICAM-3 on apoptotic cells mediates domain 1-2-dependent tethering to phagocytes. Apoptosis causes reduction in cell-surface ICAM-3 via release within microparticles. Blocking mAb (MA4) that inhibits domain 1-2 of ICAM-3 blocks apoptotic cell clearance.\",\n      \"method\": \"Novel anti-ICAM-3 mAb blocking studies, ICAM-3-deficient apoptotic leukocytes, macrophage chemotaxis assays, microparticle isolation and characterization, phagocytosis assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — uses ICAM-3-deficient cells as negative control alongside blocking mAbs, identifies microparticle mechanism, multiple functional assays (chemotaxis and tethering separately assessed)\",\n      \"pmids\": [\"22117198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ICAM-3 gene promoter activity is leukocyte-restricted and is negatively regulated by RUNX transcription factors: RUNX cognate sequences are required for promoter activity and RUNX3/Ets/C-EBP cooperative regulation; siRNA-mediated reduction of RUNX3 increases ICAM-3 mRNA levels. ICAM-3 protein levels decrease during monocyte-to-macrophage differentiation and monocyte transendothelial migration, correlating with RUNX3 increase.\",\n      \"method\": \"ICAM-3 promoter-reporter assays, chromatin immunoprecipitation (in vivo occupancy), RUNX-binding site mutagenesis, siRNA knockdown of RUNX3, protein analysis during differentiation/migration\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP confirms in vivo occupancy, promoter mutagenesis demonstrates requirement of RUNX sites, siRNA validates RUNX3 as negative regulator, multiple orthogonal methods\",\n      \"pmids\": [\"22479382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ICAM-3 expressed on macrophages functions as a recognition receptor for apoptotic neutrophils: siRNA silencing and antibody blockade of ICAM-3 on macrophages (but not neutrophils) reduces phagocytosis; blocking ICAM-3 on apoptotic neutrophil surface also reduces uptake. ICAM-3 and LFA-1 (αL/β2) co-localize at phagocytic portals on macrophages; simultaneous knockdown causes marked phagocytosis deficiency.\",\n      \"method\": \"Gene silencing (siRNA), blocking antibodies, confocal microscopy of phagocytic portals, apoptotic neutrophil phagocytosis assay\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA knockdown plus antibody blockade on both cell types combined with confocal imaging of phagocytic portals, replicated in multiple assays\",\n      \"pmids\": [\"23775590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ICAM-3 overexpression in NSCLC cells increases cell migration and invasion by upregulating MMP-2 and MMP-9 expression and activity through a signaling pathway: ICAM-3 → Akt phosphorylation → CREB activation → MMP upregulation. Blocking the Akt pathway attenuates CREB activation and reduces MMP activity and migration/invasion, regardless of p53 or PTEN status.\",\n      \"method\": \"Stable ICAM-3-overexpressing transfectants, migration/invasion assays, MMP-2/9 activity assays, Akt phosphorylation Western blot, CREB activation assays, Akt pathway inhibitors, CREB siRNA\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable OE cell lines with pathway inhibitors and siRNA knockdown, validated in two NSCLC cell lines, single lab\",\n      \"pmids\": [\"19956847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICAM-3 promotes cancer cell stemness by recruiting and binding Src kinase via a YLPL motif in its intracellular domain, thereby activating PI3K-AKT signaling that enhances SOX2 and OCT4 activity; activated p-AKT also facilitates p50 nuclear translocation enhancing ICAM-3 promoter activity creating a positive feedback loop. ICAM-3 knockdown reduces side population, sphere formation, chemo-resistance, and tumor growth in vivo.\",\n      \"method\": \"siRNA screen, shRNA knockdown, Src co-immunoprecipitation with intracellular domain, Src/PI3K inhibitors, in vivo tumor xenograft, ALDH assay, sphere formation, p50 nuclear translocation assay, ICAM-3 promoter ChIP\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP identifies Src-ICAM3 interaction via intracellular domain, pathway inhibitors and in vivo validation, but single lab study\",\n      \"pmids\": [\"29477378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICAM-3 promotes tumor metastasis through a LFA-1-ICAM-3-ERM-lamellipodia mechanism: ICAM-3 binds LFA-1 via its extracellular domain and ERM proteins via its intracellular domain, creating mechanical tension that facilitates cell separation (metastasis). ICAM-3 extracellular or intracellular domain mutants abolish ICAM-3-mediated metastasis in vitro and in vivo; blocking LFA-1/ICAM-3 interaction with LFA-1 antibody or Lifitegrast reduces metastasis.\",\n      \"method\": \"Co-IP of LFA-1 and ERM with ICAM-3, extracellular/intracellular domain mutants, in vitro and in vivo metastasis assays, LFA-1 blocking antibody and Lifitegrast treatment\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus domain mutants with in vivo validation, single lab\",\n      \"pmids\": [\"29729315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Kidins220/ARMS (a neuronal scaffold protein also expressed in T cells) co-localizes with and co-immunoprecipitates with ICAM-3 at the uropod of polarized T cells; this association requires cell polarity and is regulated by PKC. Kidins220/ARMS knockdown promotes basal and SDF-1α-induced T cell directed migration.\",\n      \"method\": \"Co-immunoprecipitation, confocal immunofluorescence colocalization, cell polarity disruption, PKC inhibition, siRNA knockdown, chemotaxis assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus colocalization with polarity-dependence validation and functional siRNA knockdown, single lab\",\n      \"pmids\": [\"21381019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Activation of ICAM-3 on human bone marrow endothelial cells by antibody cross-linking reduces electrical resistance of endothelial monolayers and causes loss of cell-cell contacts; cross-linking induces association of moesin (and later ezrin) with ICAM-3, and stimulates production of reactive oxygen species (ROS) that mediate control of endothelial integrity.\",\n      \"method\": \"Electrical resistance measurements, immunocytochemistry, biochemical pull-down/co-IP of moesin and ezrin, ROS detection\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay (resistance measurement) linked to molecular association (ERM proteins) and ROS signaling, single lab\",\n      \"pmids\": [\"14726630\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ICAM-3 (CD50) is a five-domain IgSF cell adhesion molecule constitutively expressed on all resting leukocytes that functions as a ligand for LFA-1 (CD11a/CD18) through domain 1 residues on both the ABED and GFC faces, and also binds αdβ2 integrin and DC-SIGN (via Lewis x glycans); it acts as a co-stimulatory and outside-in signaling molecule on T cells (engaging p56lck, p59fyn, Ca2+ flux, PKC, and PI3K-AKT pathways), undergoes proteolytic shedding from activated neutrophils, localizes to the T cell uropod at the APC contact initiation zone, participates in apoptotic cell recognition and clearance by macrophages via a domain 1-2-dependent tethering interaction, and drives cancer cell migration, invasion, stemness, and metastasis through an intracellular YLPL-Src-AKT-CREB-MMP axis and a LFA-1-ICAM-3-ERM mechanical tension mechanism; its expression is transcriptionally repressed by RUNX3 during monocyte-to-macrophage differentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ICAM-3 (CD50/ICAM-R) is a five-domain immunoglobulin-superfamily adhesion molecule constitutively expressed on resting leukocytes that serves as a principal ligand for the integrin LFA-1 (CD11a/CD18) and acts as a bidirectional signaling and adhesion hub at leukocyte contact sites [#0, #7]. LFA-1 binding is mediated by the N-terminal Ig-like domain 1, which is necessary and sufficient, through residues clustering on both the ABED and GFC faces — a more extensive footprint than that used by ICAM-1 — and is engaged through the LFA-1 \\u03b1-subunit I domain in a cation-dependent manner [#4, #20, #11, #19]. Beyond LFA-1, ICAM-3 is preferentially bound by the \\u03b1d\\u03b22 integrin and, via Lewis-x and high-mannose glycans on its complex-type N-linked oligosaccharides, by the dendritic-cell lectin DC-SIGN to mediate early DC\\u2013T-cell adhesion [#8, #24, #30, #27]. ICAM-3 engagement triggers outside-in signaling: it associates with the Src-family kinases p56lck and p59fyn, drives calcium flux and tyrosine phosphorylation under CD45 regulation, raises \\u03b21/\\u03b22 integrin avidity, and co-stimulates T-cell proliferation and chemokine secretion from monocytes and neutrophils [#9, #5, #10, #12, #21, #22]. The molecule polarizes to the T-cell uropod and clusters at the APC contact-initiation zone, positioning it for the earliest scanning phase of immune synapse formation, and is shed proteolytically from activated neutrophils and lymphocytes to yield a circulating soluble form [#6, #28, #14, #17]. On apoptotic leukocytes, domain 1\\u20132 of ICAM-3 switches to an alternative recognition activity that tethers dying cells and their microparticles to macrophage CD14 to drive chemoattraction and efferocytosis [#23, #31, #33]. Its leukocyte-restricted promoter is repressed by RUNX3 during monocyte-to-macrophage differentiation [#32]. In cancer cells ICAM-3 promotes migration, invasion, stemness and metastasis through an intracellular YLPL-Src-AKT-CREB-MMP axis and an LFA-1\\u2013ICAM-3\\u2013ERM mechanical-tension mechanism [#34, #35, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established the molecular identity of ICAM-3 as an IgSF adhesion molecule and a third constitutive LFA-1 ligand, defining a leukocyte-restricted adhesion receptor distinct from endothelial ICAMs.\",\n      \"evidence\": \"expression cloning, cell adhesion and antibody-blocking assays across two independent papers\",\n      \"pmids\": [\"1448173\", \"1448174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface on ICAM-3 not yet mapped\", \"Cytoplasmic signaling function unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed ICAM-3 is not merely an adhesive ligand but an active regulator that, when engaged, drives LFA-1/ICAM-1-dependent aggregation and co-stimulates proliferation, and confirmed CDw50/ICAM-3 identity.\",\n      \"evidence\": \"adhesion on purified ICAM-3, mAb blocking, immunofluorescence, proliferation assays, protein sequencing\",\n      \"pmids\": [\"7901223\", \"8325327\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates downstream of engagement undefined\", \"Mechanism of integrin avidity modulation unclear\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Localized the LFA-1 binding site to ICAM-3 domain 1 by systematic mutagenesis and structural EM, defining conserved versus specificity-conferring residues and the reciprocal LFA-1 I domain as the binding partner.\",\n      \"evidence\": \"domain-deletion chimeras, 45 point mutants, mAb epitope mapping, electron microscopy\",\n      \"pmids\": [\"8798624\", \"7531103\", \"7518468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal structure absent\", \"Conformational requirements on LFA-1 not fully resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined ICAM-3 outside-in signaling, linking engagement to Src-family kinases, calcium flux, CD45-regulated tyrosine phosphorylation, and integrin avidity upregulation.\",\n      \"evidence\": \"anti-CD50 cross-linking, Ca2+ measurement, phosphotyrosine co-IP and in vitro kinase assays, CD45 inhibitor and tyrosine-kinase inhibitor studies, adhesion assays\",\n      \"pmids\": [\"7515097\", \"7520448\", \"7515813\", \"8223855\", \"1730238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct adaptor coupling p56lck/p59fyn to ICAM-3 cytoplasmic tail not defined\", \"Whether phosphorylation is on ICAM-3 itself or associated proteins not fully resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined ICAM-3 receptor specificity and ligand promiscuity \\u2014 it binds the new \\u03b1d\\u03b22 integrin preferentially over ICAM-1 but is not a ligand for Mac-1 or p150,95 \\u2014 narrowing the set of relevant integrin partners.\",\n      \"evidence\": \"cDNA cloning of \\u03b1d, transfectant adhesion comparisons, bidirectional purified-protein adhesion assays\",\n      \"pmids\": [\"8777714\", \"7737271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context of \\u03b1d\\u03b22\\u2013ICAM-3 binding unclear\", \"Affinity hierarchy among integrin ligands not quantified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrated that ICAM-3 surface levels are dynamically controlled by proteolytic shedding from activated neutrophils and lymphocytes, generating a circulating soluble form.\",\n      \"evidence\": \"internalization assays ruling out endocytosis, protease inhibition, detection of shed protein in supernatant and plasma, ELISA/immunoblot size comparison\",\n      \"pmids\": [\"7525295\", \"7876564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the responsible protease not established\", \"Functional role of soluble ICAM-3 in vivo unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Refined the LFA-1 binding footprint, showing it spans both ABED and GFC faces of domain 1 \\u2014 more extensive and partly distinct from ICAM-1 \\u2014 explaining selective ligand engagement.\",\n      \"evidence\": \"18-residue site-directed mutagenesis with LFA-1 adhesion assays\",\n      \"pmids\": [\"9686599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure of the complex\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Established epitope-specific outside-in signaling on myeloid cells, with domain-1-directed engagement driving chemokine secretion, spreading, and \\u03b22-integrin-dependent aggregation through tyrosine and PKC kinases.\",\n      \"evidence\": \"Fab/F(ab')2 fragment engagement controls, chemokine ELISA, kinase and cytoskeleton assays, anti-\\u03b22 blocking\",\n      \"pmids\": [\"9605163\", \"9834117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cytoplasmic effectors transducing the signal undefined\", \"Why different domain-1 mAbs give opposite effects (HP2/19 vs CAL3.10) mechanistically unexplained\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed a context switch in ICAM-3 function: on apoptotic leukocytes domain 1 changes binding preference from LFA-1 to a macrophage CD14-dependent recognition activity for clearance of dying cells.\",\n      \"evidence\": \"mAb blockade of candidate macrophage receptors, ICAM-3 transfection into non-leukocytes, multiple apoptosis stimuli\",\n      \"pmids\": [\"10352301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the apoptotic conformational/glycan change not defined\", \"Direct CD14\\u2013ICAM-3 binding not biochemically reconstituted\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified DC-SIGN as a high-affinity ICAM-3 receptor mediating transient DC\\u2013T-cell adhesion required for primary immune response initiation, extending ICAM-3 ligand repertoire beyond integrins.\",\n      \"evidence\": \"DC-SIGN expression identification, binding assays, anti-DC-SIGN inhibition of DC\\u2013T adhesion and proliferation\",\n      \"pmids\": [\"10721994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Carbohydrate basis of binding not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the glycan structures of ICAM-3 and identified the high-mannose component as a candidate DC-SIGN ligand, linking glycosylation to lectin recognition.\",\n      \"evidence\": \"hydrazinolysis, lectin chromatography, glycosidase digestion, methylation analysis\",\n      \"pmids\": [\"11179968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional contribution of each glycan species to DC-SIGN binding not directly tested here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed ICAM-3 at the spatiotemporal start of immune-synapse formation, showing it clusters at the T-cell\\u2013APC contact-initiation zone before antigen recognition and supports the scanning phase.\",\n      \"evidence\": \"time-lapse live-cell imaging, antibody blocking of conjugate formation, early signaling and cytoskeletal readouts\",\n      \"pmids\": [\"11812993\", \"7525599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoskeletal adaptors anchoring ICAM-3 at the uropod/contact zone not identified here\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the carbohydrate determinant of DC-SIGN recognition as Lewis-x on myeloid-cell ICAM-3, synthesized primarily by FUT9, refining the glycan-dependent lectin interaction.\",\n      \"evidence\": \"binding with native ICAM-3, MALDI-TOF glycan identification, FUT isoform cotransfection, Lewis-x mAb staining\",\n      \"pmids\": [\"17145745\", \"14970226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lymphocyte-derived ICAM-3 binds DC-SIGN by a distinct (mannose) determinant not fully dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected ICAM-3 to efferocytosis machinery, showing apoptotic-cell-derived ICAM-3-bearing microparticles act as macrophage chemoattractants and that domain 1\\u20132 tethers dying cells to phagocytes; also identified Kidins220/ARMS as a uropod-associated partner restraining migration.\",\n      \"evidence\": \"ICAM-3-deficient apoptotic cells, blocking mAbs, chemotaxis/phagocytosis assays, microparticle isolation; co-IP and PKC-regulated colocalization for Kidins220\",\n      \"pmids\": [\"22117198\", \"21381019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor on macrophages capturing microparticle ICAM-3 not fully defined\", \"Kidins220\\u2013ICAM-3 interaction is single-lab co-IP\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified RUNX3 as a negative transcriptional regulator of the leukocyte-restricted ICAM-3 promoter, explaining the downregulation of ICAM-3 during monocyte-to-macrophage differentiation.\",\n      \"evidence\": \"promoter-reporter assays, ChIP occupancy, RUNX-site mutagenesis, RUNX3 siRNA, differentiation tracking\",\n      \"pmids\": [\"22479382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Activating transcription factors driving constitutive leukocyte expression less defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended ICAM-3 function into cancer, defining an intracellular YLPL\\u2013Src\\u2013AKT axis driving stemness via SOX2/OCT4 and an LFA-1\\u2013ICAM-3\\u2013ERM mechanical-tension mechanism driving metastasis, building on the earlier AKT\\u2013CREB\\u2013MMP migration pathway.\",\n      \"evidence\": \"shRNA knockdown, Src/ERM co-IP with intracellular domain, domain mutants, pathway inhibitors, xenografts, Lifitegrast/LFA-1 blockade; stable OE migration/invasion assays\",\n      \"pmids\": [\"29477378\", \"29729315\", \"19956847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab studies for each cancer mechanism\", \"YLPL\\u2013Src and ERM associations not structurally resolved\", \"Direct in vivo clinical relevance unestablished\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same domain-1 surface and cytoplasmic tail are toggled between LFA-1 adhesion, apoptotic CD14 recognition, and intracellular Src/ERM engagement \\u2014 and which proteases and conformational switches govern these transitions \\u2014 remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic structure of ICAM-3 in complex with any partner\", \"Shedding protease unidentified\", \"Mechanism of apoptosis-induced functional switch undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 7, 2, 23]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 21, 22, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 10, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 14, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 24, 23, 33]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 21, 22, 35]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 2, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [34, 35, 36]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ITGAL\", \"ITGB2\", \"ITGAD\", \"CD209\", \"LCK\", \"FYN\", \"EZR\", \"KIDINS220\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}